Lilly licenses PDL BioPharma's antibody humanisation technology
This article was originally published in Scrip
Executive Summary
Lilly has obtained a non-exclusive licence to patents covering monoclonal antibody humanisation owned by PDL BioPharma for use with teplizumab, a humanised anti-CD3 monoclonal antibody that Lilly is developing with MacroGenics, and other potential next-generation anti-CD3 molecules. Teplizumab is in a Phase II/III pivotal trial for type 1 diabetes.